Contra

Chemed Reports Fourth-Quarter 2023 Results

Retrieved on: 
Tuesday, February 27, 2024

Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2023, versus the comparable prior-year period.

Key Points: 
  • Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2023, versus the comparable prior-year period.
  • Chemed uses certain non-GAAP metrics such as EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share, to provide additional context and perspective to reported operational results.
  • As of December 31, 2023, Chemed had total cash and cash equivalents of $264.0 million and no current or long-term debt.
  • Chemed’s 2023 adjusted earnings per diluted share was $20.30, including $1.04 per share for costs associated with the 2023 portion of the Retention Program.

Nintendo Download: A Tangled Mess of Magic

Retrieved on: 
Thursday, February 22, 2024

A “Rare” Quintet – Five games, all developed by Rare, are now available on the Nintendo Switch Online and Nintendo Switch Online + Expansion Pack collections!

Key Points: 
  • A “Rare” Quintet – Five games, all developed by Rare, are now available on the Nintendo Switch Online and Nintendo Switch Online + Expansion Pack collections!
  • Nintendo Switch Online members can enjoy KILLER INSTINCT and BATTLETOADS IN BATTLEMANIACS as part of the Super NES – Nintendo Switch Online library, and SNAKE RATTLE N ROLL and R.C.
  • Nintendo Switch Online + Expansion Pack members can play those titles and Blast Corps, which brings destructive vehicular action to the Nintendo 64 – Nintendo Switch Online library.
  • Also new this week in Nintendo eShop on Nintendo Switch:

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Retrieved on: 
Tuesday, January 16, 2024

Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.

Key Points: 
  • Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.
  • The FDA also granted NRX-101 Fast Track designation for cUTI, which additionally allows for rolling submission of the Company's New Drug Application.
  • On the basis of this advance, NRx is seeking partners with active involvement in urology, infectious disease and/or women's health for commercialization of NRX-101.
  • NRx thanks the US FDA for its rapid award of QIDP designation for cUTI and pyelonephritis.

3Spine Announces Completion of FDA Clinical Trial Enrollment Achieving 325 Surgeries in 2023

Retrieved on: 
Wednesday, January 10, 2024

The company enrolled a larger fusion cohort in an adaptive statistical design to improve propensity score matching between data sets.

Key Points: 
  • The company enrolled a larger fusion cohort in an adaptive statistical design to improve propensity score matching between data sets.
  • The trials involved patients experiencing chronic leg and back pain ranging in age from 23 to 79 across 14 U.S. states.
  • 3Spine plans to seek FDA approval through the Premarket Approval pathway.
  • Information on the real-world fusion clinical trial is available at NCT04823858 .

NCLA Reply Brief in Relentless Case Counters Government’s Claims on Judicial Deference to Agencies

Retrieved on: 
Friday, January 5, 2024

Washington, D.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed a reply brief in Relentless Inc., et al.

Key Points: 
  • Washington, D.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed a reply brief in Relentless Inc., et al.
  • NCLA addresses two core problems with Chevron deference that NCLA founder Philip Hamburger has emphasized for years.
  • First, employing such deference abandons a judge’s Article III duty of judicial independence.
  • NCLA urges the Court to vacate Respondents’ rule, which lower courts only upheld by applying Chevron deference.

New Guidelines on Men with Erectile Dysfunction and Cardiac Health Published in the Journal of Sexual Medicine Concludes PDE-5 Inhibitors are Still Safe for the Cardiovascular System

Retrieved on: 
Thursday, January 4, 2024

Their summary and guidelines have now been published in the Journal of Sexual Medicine.

Key Points: 
  • Their summary and guidelines have now been published in the Journal of Sexual Medicine.
  • They determined that PDE-5 inhibitors are still safe for the cardiovascular system.
  • The conference was funded by an unrestricted grant from Sanofi to readdress the cardiovascular workup of men presenting with ED and the cardiovascular safety of the phosphodiesterase-5 (PDE-5) inhibitors for treating ED.
  • Patients with ED should be characterized as low-risk, intermediate (or indeterminable), or high-risk of developing a cardiac event with sexual activity.

Galaxy Gaming Reports Q3 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023

LAS VEGAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galaxy Gaming, Inc. (OTCQB: GLXZ), a developer and distributor of casino table games and enhanced systems for land-based casinos and iGaming content, announced today its financial results for the quarter and nine months ended September 30, 2023.

Key Points: 
  • LAS VEGAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galaxy Gaming, Inc. (OTCQB: GLXZ), a developer and distributor of casino table games and enhanced systems for land-based casinos and iGaming content, announced today its financial results for the quarter and nine months ended September 30, 2023.
  • “We had a sequential decline in revenue in Q3 principally because sales of perpetual licenses were lower in Q3 than in Q1 and Q2.
  • “Excluding those sales, revenue in GG Core was $3.8 million in Q3 ‘23 as compared to $3.9 million in Q3 ‘22.
  • In GG Digital, revenue (net) was $1.8 million in Q3 ‘23 as compared to $2.0 million in Q3 ‘22.

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include:

Key Points: 
  • — Reduced loss from operations by 81% vs. Q3 2022 —
    SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.
  • Highlights include:
    $5.1 million in net product sales of Phexxi® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023.
  • Third quarter total operating expenses were $8.7 million for 2023, a decrease of 65% as compared with the same period last year.
  • Narrowed loss from operations by 81% in the third quarter of 2023 as compared with the prior year quarter.

Expensify Announces Q3 2023 Results

Retrieved on: 
Tuesday, November 7, 2023

With luck, our long-awaited migration of Expensify Classic to New Expensify should be actively underway by this time next quarter.

Key Points: 
  • With luck, our long-awaited migration of Expensify Classic to New Expensify should be actively underway by this time next quarter.
  • Expensify Card accounting treatment - The company will become the program manager of the Expensify Card starting in late Q4.
  • The following statements are forward-looking and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.
  • There can be no assurance that the Company will achieve the results expressed by this guidance.

Chemed Reports Third-Quarter 2023 Results – Increases Full Year Guidance

Retrieved on: 
Wednesday, October 25, 2023

Starting with the September 30, 2023 quarter, Chemed is no longer excluding the cost of the Retention Program when presenting non-GAAP operating metrics in current or prior periods.

Key Points: 
  • Starting with the September 30, 2023 quarter, Chemed is no longer excluding the cost of the Retention Program when presenting non-GAAP operating metrics in current or prior periods.
  • As of September 30, 2023, Chemed had total cash and cash equivalents of $173 million and no current or long-term debt.
  • This guidance includes $1.18 per share of after-tax costs related to the 2023 portion of the Retention Program.
  • This revised 2023 guidance compares to previous guidance, as recast to no longer exclude costs associated with the Retention Program, of $18.72 to $18.92, including.